4.7 Article

Transcriptome instability as a molecular pan-cancer characteristic of carcinomas

期刊

BMC GENOMICS
卷 15, 期 -, 页码 -

出版社

BMC
DOI: 10.1186/1471-2164-15-672

关键词

Alternative splicing; Carcinomas; Exon microarray; Splicing factor; Tissue specificity

资金

  1. Norwegian Health Region South-East [2011024, 2012067]
  2. Norwegian Cancer Society [PR-2006-0442, PR-2007-0166]
  3. Research Council of Norway through its Centres of Excellence funding scheme [179571]

向作者/读者索取更多资源

Background: We have previously proposed transcriptome instability as a genome-wide, pre-mRNA splicing-related characteristic of colorectal cancer. Here, we explore the hypothesis of transcriptome instability being a general characteristic of cancer. Results: Exon-level microarray expression data from ten cancer datasets were analyzed, including breast cancer, cervical cancer, colorectal cancer, gastric cancer, lung cancer, neuroblastoma, and prostate cancer (555 samples), as well as paired normal tissue samples from the colon, lung, prostate, and stomach (93 samples). Based on alternative splicing scores across the genomes, we calculated sample-wise relative amounts of aberrant exon skipping and inclusion. Strong and non-random (P < 0.001) correlations between these estimates and the expression levels of splicing factor genes (n = 280) were found in most cancer types analyzed (breast-, cervical-, colorectal-, lung-and prostate cancer). This suggests a biological explanation for the splicing variation. Surprisingly, these associations prevailed in pan-cancer analyses. This is in contrast to the tissue and cancer specific patterns observed in comparisons across healthy tissue samples from the colon, lung, prostate, and stomach, and between paired cancer-normal samples from the same four tissue types. Conclusion: Based on exon-level expression profiling and computational analyses of alternative splicing, we propose transcriptome instability as a molecular pan-cancer characteristic. The affected cancers show strong and non-random associations between low expression levels of splicing factor genes, and high amounts of aberrant exon skipping and inclusion, and vice versa, on a genome-wide scale.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

Article Endocrinology & Metabolism

Long-term first-in-man Phase I/II study of an adjuvant dendritic cell vaccine in patients with high-risk prostate cancer after radical prostatectomy

Anne M. A. Tryggestad, Karol Axcrona, Ulrika Axcrona, Iris Bigalke, Bjorn Brennhovd, Else M. Inderberg, Turid K. Honnashagen, Lisbeth J. Skoge, Guri Solum, Stein Saeboe-Larssen, Dag Josefsen, Richard W. Olaussen, Steinar Aamdal, Rolf I. Skotheim, Tor A. Myklebust, Dolores J. Schendel, Wolfgang Lilleby, Svein Dueland, Gunnar Kvalheim

Summary: This study aimed to reduce the risk of biochemical relapse in high-risk prostate cancer patients after robot-assisted laparoscopic prostatectomy by administering personalized dendritic cell vaccines as adjuvant therapy. The results showed promising efficacy of the vaccine in reducing biochemical relapse incidence, as well as associations between baseline immune response and vaccine response during the vaccination period. Further investigation in larger cohorts is warranted to validate these findings and explore the potential of dendritic cell vaccines in post-surgical treatment of high-risk prostate cancer.

PROSTATE (2022)

Letter Gastroenterology & Hepatology

Genetic Cancer Susceptibility in Adolescents and Adults 25 Years or Younger With Colorectal Cancer

Marjolijn C. J. Jongmans, Junxiao Zhang, Roland P. Kuiper, Nicoline Hoogerbrugge, Marjolijn J. L. Ligtenberg, Richarda M. de Voer

GASTROENTEROLOGY (2022)

Article Oncology

Somatic mutations reveal complex metastatic seeding from multifocal primary prostate cancer

Kristina T. Carm, Bjarne Johannessen, Mari Bogaard, Anne Cathrine Bakken, Aase Maltau, Andreas M. Hoff, Ulrika Axcrona, Karol Axcrona, Ragnhild A. Lothe, Rolf Skotheim

Summary: Our study highlights the spatio-temporal heterogeneity of multifocal prostate cancer and emphasizes the importance of testing a recent sample in genomics-based precision medicine for metastatic prostate cancer.

INTERNATIONAL JOURNAL OF CANCER (2023)

Article Oncology

Exome sequencing of affected duos and trios uncovers PRUNE2 as a novel prostate cancer predisposition gene

Marta Cardoso, Sofia Maia, Andreia Brandao, Ruta Sahasrabudhe, Paul Lott, Natalia Belter, Luis G. Carvajal-Carmona, Paula Paulo, Manuel R. Teixeira

Summary: The study identified PRUNE2 as a novel prostate cancer predisposition gene, with pathogenic/likely pathogenic germline variants found in 2.8% of the patients. This is the first report of such variants in PRUNE2 in patients with early-onset/familial prostate cancer.

BRITISH JOURNAL OF CANCER (2023)

Article Oncology

Genotype-first approach to identify associations between CDH1 germline variants and cancer phenotypes: a multicentre study by the European Reference Network on Genetic Tumour Risk Syndromes

Jose Garcia-Pelaez, Rita Barbosa-Matos, Silvana Lobo, Alexandre Dias, Luzia Garrido, Sergio Castedo, Sonia Sousa, Hugo Pinheiro, Liliana Sousa, Rita Monteiro, Joaquin J. Maqueda, Susana Fernandes, Fatima Carneiro, Nadia Pinto, Carolina Lemos, Carla Pinto, Manuel R. Teixeira, Stefan Aretz, Svetlana Bajalica-Lagercrantz, Judith Balmana, Ana Blatnik, Patrick R. Benusiglio, Maud Blanluet, Vincent Bours, Hilde Brems, Joan Brunet, Daniele Calistri, Gabriel Capella, Sergio Carrera, Chrystelle Colas, Karin Dahan, Robin de Putter, Camille Desseignes, Elena Dominguez-Garrido, Conceicao Egas, D. Gareth Evans, Damien Feret, Eleanor Fewings, Rebecca C. Fitzgerald, Florence Coulet, Maria Garcia-Barcina, Maurizio Genuardi, Lisa Golmard, Karl Hackmann, Helen Hanson, Elke Holinski-Feder, Robert Huneburg, Mateja Krajc, Kristina Lagerstedt-Robinson, Conxi Lazaro, Marjolijn J. L. Ligtenberg, Cristina Martinez-Bouzas, Sonia Merino, Genevieve Michils, Srdjan Novakovic, Ana Patino-Garcia, Guglielmina Nadia Ranzani, Evelin Schrock, Ines Silva, Catarina Silveira, Jose L. Soto, Isabel Spier, Verena Steinke-Lange, Gianluca Tedaldi, Maria-Isabel Tejada, Emma R. Woodward, Marc Tischkowitz, Nicoline Hoogerbrugge, Carla Oliveira

Summary: This study analyzed families carrying rare CDH1 variants, comparing the cancer spectrum in carriers of pathogenic or likely pathogenic variants (PV/LPV) or missense variants of unknown significance, and evaluated the performance of expanded criteria for CDH1 testing. The results showed that PV/LPV carriers were positively associated with lobular breast cancer, diffuse gastric cancer, and gastric cancer, while missense variants of unknown significance did not show this positive association.

LANCET ONCOLOGY (2023)

Review Gastroenterology & Hepatology

Gastric Cancer: A Practical Review on Management of Individuals with Hereditary or Familial Risk for Gastric Cancer

Marisa Linhares, Claudia Marques Pinto, Diogo Libanio, Manuel R. Teixeira, Mario Dinis-Ribeiro, Catarina Brandao

Summary: Gastric adenocarcinoma is a common and deadly cancer worldwide. Screening the general population is recommended in eastern countries, but may not be cost-effective in low to intermediate-risk countries. Therefore, it is important to identify high-risk populations for adequate screening and surveillance. This review summarizes the data required to identify individuals at risk and highlights the importance of hereditary syndromes and screening protocols.

GE PORTUGUESE JOURNAL OF GASTROENTEROLOGY (2023)

Article Genetics & Heredity

Evaluating approaches for constructing polygenic risk scores for prostate cancer in men of African and European ancestry

Burcu F. Darst, Jiayi Shen, Ravi K. Madduri, Alexis A. Rodriguez, Yukai Xiao, Xin Sheng, Edward J. Saunders, Tokhir Dadaev, Mark N. Brook, Thomas J. Hoffmann, Kenneth Muir, Peggy Wan, Loic Le Marchand, Lynne Wilkens, Ying Wang, Johanna Schleutker, Robert J. MacInnis, Cezary Cybulski, David E. Neal, Borge G. Nordestgaard, Sune F. Nielsen, Jyotsna Batra, Judith A. Clements, Henrik Gronberg, Nora Pashayan, Ruth C. Travis, Jong Y. Park, Demetrius Albanes, Stephanie Weinstein, Lorelei A. Mucci, David J. Hunter, Kathryn L. Penney, Catherine M. Tangen, Robert J. Hamilton, Marie-Elise Parent, Janet L. Stanford, Stella Koutros, Alicja Wolk, Karina D. Sorensen, William J. Blot, Edward D. Yeboah, James E. Mensah, Yong-Jie Lu, Daniel J. Schaid, Stephen N. Thibodeau, Catharine M. West, Christiane Maier, Adam S. Kibel, Geraldine Cancel-Tassin, Florence Menegaux, Esther M. John, Eli Marie Grindedal, Kay-Tee Khaw, Sue A. Ingles, Ana Vega, Barry S. Rosenstein, Manuel R. Teixeira, Manoli Kogevinas, Lisa Cannon-Albright, Chad Huff, Luc Multigner, Radka Kaneva, Robin J. Leach, Hermann Brenner, Ann W. Hsing, Rick A. Kittles, Adam B. Murphy, Christopher J. Logothetis, Susan L. Neuhausen, William B. Isaacs, Barbara Nemesure, Anselm J. Hennis, John Carpten, Hardev Pandha, Kim De Ruyck, Jianfeng Xu, Azad Razack, Soo-Hwang Teo, Lisa F. Newcomb, Jay H. Fowke, Christine Neslund-Dudas, Benjamin A. Rybicki, Marija Gamulin, Nawaid Usmani, Frank Claessens, Manuela Gago-Dominguez, Jose Esteban Castelao, Paul A. Townsend, Dana C. Crawford, Gyorgy Petrovics, Graham Casey, Monique J. Roobol, Jennifer F. Hu, Sonja I. Berndt, Stephen K. van den Eeden, Douglas F. Easton, Stephen J. Chanock, Michael B. Cook, Fredrik Wiklund, John S. Witte, Rosalind A. Eeles, Zsofia Kote-Jarai, Stephen Watya, John M. Gaziano, Amy C. Justice, David V. Conti, Christopher A. Haiman

Summary: In this study, the predictive ability of several genome-wide polygenic risk score (GW-PRS) approaches was compared to a recently developed PRS of established prostate cancer-risk variants. The findings suggest that the PRS269 developed from multi-ancestry GWASs and fine-mapping has better predictive ability for prostate cancer risk compared to current GW-PRS approaches.

AMERICAN JOURNAL OF HUMAN GENETICS (2023)

Article Oncology

Ovarian cancer pathology characteristics as predictors of variant pathogenicity in BRCA1 and BRCA2

Denise G. O'Mahony, Susan J. Ramus, Melissa C. Southey, Nicola S. Meagher, Andreas Hadjisavvas, Esther M. John, Ute Hamann, Evgeny N. Imyanitov, Irene L. Andrulis, Priyanka Sharma, Mary B. Daly, Christopher R. Hake, Jeffrey N. Weitzel, Anna Jakubowska, Andrew K. Godwin, Adalgeir Arason, Anita Bane, Jacques Simard, Penny Soucy, Maria A. Caligo, Phuong L. Mai, Kathleen B. M. Claes, Manuel R. Teixeira, Wendy K. Chung, Conxi Lazaro, Peter J. Hulick, Amanda E. Toland, Inge Sokilde Pedersen, Susan L. Neuhausen, Ana Vega, Miguel de la Hoya, Heli Nevanlinna, Mallika Dhawan, Valentina Zampiga, Rita Danesi, Liliana Varesco, Viviana Gismondi, Valerio Gaetano Vellone, Paul A. James, Ramunas Janavicius, Liene Nikitina-Zake, Finn Cilius Nielsen, Thomas van Overeem Hansen, Tanja Pejovic, Ake Borg, Johanna Rantala, Kenneth Offit, Marco Montagna, Katherine L. Nathanson, Susan M. Domchek, Ana Osorio, Maria J. Garcia, Beth Y. Karlan, Anna De Fazio, David Bowtell, Lesley McGuffog, Goska Leslie, Michael T. Parsons, Thilo Doerk, Lisa-Marie Speith, Elizabeth Santana dos Santos, Alexandre Andre B. A. da Costa, Paolo Radice, Paolo Peterlongo, Laura Papi, Christoph Engel, Eric Hahnen, Rita K. Schmutzler, Barbara Wappenschmidt, Douglas F. Easton, Marc Tischkowitz, Christian F. Singer, Yen Yen Tan, Alice S. Whittemore, Weiva Sieh, James D. Brenton, Drakoulis Yannoukakos, Florentia Fostira, Irene Konstantopoulou, Jana Soukupova, Michal Vocka, Georgia Chenevix-Trench, Paul D. P. Pharoah, Antonis C. Antoniou, David E. Goldgar, Amanda B. Spurdle, Kyriaki Michailidou, Marian J. E. Mourits, Fabienne Lesueur

Summary: This study assessed the utility of ovarian tumour characteristics as predictors of BRCA1 and BRCA2 variant pathogenicity and provided evidence for improved classification and clinical management of carriers.

BRITISH JOURNAL OF CANCER (2023)

Article Biochemistry & Molecular Biology

Evaluation of PIK3CA mutations in advanced ER+/HER2-breast cancer in Portugal - U-PIK Project

Ana Peixoto, Luis Cirnes, Ana Luisa Carvalho, Maria Joao Andrade, Maria Jose Brito, Paula Borralho, Pedro M. Borralho, Ana Sofia Carneiro, Lisandra Castro, Lurdes Correia, Maria Rita Dionisio, Carlos Faria, Paulo Figueiredo, Ana Gomes, Joana Paixao, Manuela Pinheiro, Hugo Prazeres, Joana Ribeiro, Natalia Salgueiro, Fernando C. Schmitt, Fatima Silva, Ana Rita Silvestre, Ana Carla Sousa, Joana Almeida-Tavares, Manuel R. Teixeira, Saudade Andre, Jose Carlos Machado

Summary: The U-PIK project aimed to validate and implement the PIK3CA mutation testing in multiple Portuguese centers, and the testing results showed high concordance rates between the method used by each tester center and NGS, demonstrating the importance of this test in clinical practice for ER+/HER2-BC patients eligible for PI3K alpha inhibitor treatment.

FRONTIERS IN MOLECULAR BIOSCIENCES (2023)

Article Oncology

PREDICT validity for prognosis of breast cancer patients with pathogenic BRCA1/2 variants

Taru Muranen, Anna Morra, Sofia R. Khan, Daniel K. Barnes, Manjeet Bolla, Joe Dennis, Renske Keeman, Goska T. Leslie, Michael Parsons, Qin U. Wang, Thomas Ahearn, Kristiina L. Aittomaeki, Irene K. Andrulis, Banu Arun, Sabine Behrens, Katarzyna E. Bialkowska, Stig J. Bojesen, Nicola Camp, Jenny Chang-Claude, Kamila Czene, Peter M. Devilee, Susan M. Domchek, Alison Dunning, Christoph Engel, D. Gareth Evans, Manuela Gago-Dominguez, Montserrat Garcia-Closas, Anne-Marie Gerdes, Gord Glendon, Pascal Guenel, Eric Hahnen, Ute Hamann, Helen J. Hanson, Maartje Hooning, Reiner Hoppe, Louise Izatt, Anna A. Jakubowska, Paul N. James, Vessela Kristensen, Fiona J. Lalloo, Geoffrey Lindeman, Arto Mannermaa, Sara L. Margolin, Susan G. Neuhausen, William Newman, Paolo Peterlongo, Kelly-Anne Phillips, Miquel Angel Pujana, Johanna Rantala, Karina Ronlund, Emmanouil K. Saloustros, Rita Schmutzler, Andreas F. Schneeweiss, Christian Singer, Maija Suvanto, Yen Yen R. Tan, Manuel Teixeira, Mads Thomassen, Marc Tischkowitz, Vishakha Tripathi, Barbara Wappenschmidt, Emily F. Zhao, Douglas C. Easton, Antonis Antoniou, Georgia Chenevix-Trench, Paul D. P. K. Pharoah, Marjanka Schmidt, Carl Blomqvist, Heli Nevanlinna

Summary: This study assessed the PREDICT v 2.2 for prognosis of breast cancer patients with pathogenic germline BRCA1 and BRCA2 variants. The results showed that PREDICT had modest discrimination for BRCA1 carrier patients with ER-negative breast cancer, but clearly distinguished the high-mortality group from lower risk categories. However, for ER-positive breast cancer, the discrimination was slightly lower in BRCA2 variant carriers, and the inclusion of tumor grade distorted the prognostic estimates.

NPJ BREAST CANCER (2023)

Article Oncology

Genetic landscape of homologous recombination repair genes in early-onset/familial prostate cancer patients

Paula Paulo, Marta Cardoso, Andreia Brandao, Pedro Pinto, Ariane Falconi, Manuela Pinheiro, Nuno Cerveira, Rui Silva, Catarina Santos, Carla Pinto, Ana Peixoto, Sofia Maia, Manuel R. Teixeira

Summary: Using targeted next-generation sequencing (T-NGS), this study examined 462 cases of early-onset/familial PrCa and identified a link between mutations in the IGF2R gene and susceptibility to PrCa.

GENES CHROMOSOMES & CANCER (2023)

Article Oncology

Frequency of CDH1, CTNNA1 and CTNND1 Germline Variants in Families with Diffuse and Mixed Gastric Cancer

Joana Guerra, Carla Pinto, Pedro Pinto, Manuela Pinheiro, Catarina Santos, Ana Peixoto, Carla Escudeiro, Ana Barbosa, Miguel Porto, Ines Francisco, Paula Lopes, Ana Raquel Isidoro, Ana Luisa Cunha, Cristina Albuquerque, Isabel Claro, Carla Oliveira, Joao Silva, Manuel R. Teixeira

Summary: This study aimed to evaluate the contribution of CTNNA1 and CTNND1 germline variants to hereditary diffuse gastric cancer (HDGC) and compare the frequencies of CDH1 and CTNNA1 (and eventually CTNND1) germline variants between patients with diffuse and mixed gastric carcinomas. The findings revealed a high frequency of CDH1 pathogenic variants in HDGC patients, while the frequency of CTNNA1 and CTNND1 pathogenic variants was lower. No pathogenic variants were found in CDH1 and CTNNA1 in patients with mixed gastric cancer, suggesting that this tumor type may not be included in the genetic testing criteria.

CANCERS (2023)

Meeting Abstract Medicine, General & Internal

EXOME SEQUENCING OF AFFECTED DUOS AND TRIOS UNCOVERS PRUNE2 AS A NOVEL PROSTATE CANCER PREDISPOSITION GENE

Marta Cardoso, Sofia Maia, Andreia Brandao, Ruta Sahasrabudhe, Paul Lott, Natalia Belter, Luis G. Carvajal-Carmona, Paula Paulo, Manuel R. Teixeira

MEDICINE (2023)

Meeting Abstract Medicine, General & Internal

BUB1B MONOALLELIC GERMLINE VARIANTS CONTRIBUTE TO PROSTATE CANCER PREDISPOSITION BY TRIGGERING CHROMOSOMAL INSTABILITY

Maria P. Silva, Luisa T. Ferreira, Natercia F. Bras, Lurdes Torres, Andreia Brandao, Manuela Pinheiro, Marta Cardoso, Joana Vieira, Carlos M. Palmeira, Gabriela Martins, Sofia Maia, Helder Maiato, Manuel R. Teixeira, Paula Paulo

MEDICINE (2023)

Article Cell & Tissue Engineering

Cellular Aging Secretes: a Comparison of Bone-Marrow-Derived and Induced Mesenchymal Stem Cells and Their Secretome Over Long-Term Culture

Ana Marote, Diogo Santos, Barbara Mendes-Pinheiro, Claudia Serre-Miranda, Sandra Anjo, Joana Vieira, Filipa Ferreira-Antunes, Joana Sofia Correia, Caroline Borges-Pereira, Andreia G. Pinho, Jonas Campos, Bruno Manadas, Manuel R. Teixeira, Margarida Correia-Neves, Luisa Pinto, Pedro M. Costa, Laurent Roybon, Antonio J. Salgado

Summary: This study compared the secretomes of long-term cultured BM-MSCs and iMSCs, and conducted a comprehensive characterization of both sources. The results showed that although there were significant differences in proliferation between the two sources, the secretome composition of both sources was similar in pre-senescent and senescent states. These findings suggest that shifting from BM-MSCs to a more advantageous source like iMSCs may yield similar therapeutic effects as the gold-standard MSC source.

STEM CELL REVIEWS AND REPORTS (2023)

暂无数据